
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Methylconalamin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of WP205 in Healthy Subjects
Details : Methylconalamin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 05, 2025
Lead Product(s) : Methylconalamin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Huperzine A CR Tablets Safety and Efficacy In Mild-Moderate Alzheimer’s Dementia
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 15, 2025
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cognitive Dysfunction-associated with Brain Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 26, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fordine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Zhejiang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Fordine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Zhejiang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Huperzine A is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications-associated with Subarachnoid Hemorrhage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2022

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bromihexine HCl
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on the Pharmacokinetics of Bromine Hexane Hydrochloride Tablets in Healthy Adults
Details : Bromihexine HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Bromihexine HCl
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ginkgo Biloba is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina Pectoris-associated with Depression.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bromhexine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bromhexine HCl is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Pneumonia-associated with COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : Bromhexine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Second Affiliated Hospital of Wenzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Xiyuan Hospital, China Academy of Chinese Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ginkgo Biloba is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 30, 2018
Lead Product(s) : Ginkgo Biloba
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Xiyuan Hospital, China Academy of Chinese Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All